Tags: Asceneuron
Select Another Tag
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
blog
August 2, 2018
Top Five Highlights from AAIC 2018
The ADDF looks back at the 2018 Alzheimer's Association International Conference.
blog
September 21, 2016
Looking Ahead on World Alzheimer’s Day
On World Alzheimer’s Day, we celebrate the progress made toward finding effective treatments and look toward the future.
announcements
April 9, 2015
Asceneuron Awarded Alzheimer’s Drug Discovery Foundation Grant
Asceneuron SA, an emerging leader in small molecule therapeutics targeting tauopathies for Alzheimer's and related neurodegenerative diseases, was awarded a $325,000 grant from the ADDF to support the development of its tau modulators.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
57 West 57th Street, Suite 904
New York, NY 10019
info@alzdiscovery.org
212.901.8000
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).